Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Elpidia Balbastro

Medical Oncology Opelousas, LA Medical Doctor

NPI 1386614345 CMS profile 289097

1200 Hospital Dr Ste 2, Opelousas, LA 70570

Open in the dashboard

General payments

$648

37 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Elpidia Balbastro of Opelousas, LA is reported in the CMS Open Payments database as having received $648 across 37 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $34 2
2023 General $134 8
2022 General $146 8
2021 General $25 2
2019 General $309 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elpidia Balbastro
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Elpidia Balbastro were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Elpidia Balbastro Medical Oncology median Middle half National median
2019 $309 $968 $140–$6,658 $163
2020 $0 $747 $102–$5,891 $114
2021 $25 $430 $50–$4,098 $132
2022 $146 $812 $127–$4,907 $149
2023 $134 $957 $144–$5,248 $160
2024 $34 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $171 11 payments
  2. Aptevo Therapeutics Inc $100 3 payments
  3. Gilead Sciences, Inc. $83 5 payments
  4. Janssen Biotech, Inc. $45 3 payments
  5. Merck Sharp & Dohme Corporation $34 2 payments
  6. Daiichi Sankyo Inc. $33 2 payments
  7. Pharmacyclics LLC, An AbbVie Company $29 2 payments
  8. Progenics Pharmaceuticals, Inc. $25 1 payment
  9. Genentech USA, Inc. $19 1 payment
  10. Jazz Pharmaceuticals Inc. $19 1 payment
  11. Other $90 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $521 32 payments
  2. Education $126 5 payments
Products named General payments · program years 2019–2024
  1. IXINITY $100 3 payments
  2. IBRANCE $83 5 payments
  3. Trodelvy $71 4 payments
  4. DARZALEX $45 3 payments
  5. IMBRUVICA Oncology $45 3 payments
  6. LORBRENA $42 3 payments
  7. BAVENCIO $42 3 payments
  8. ENHERTU $33 2 payments
  9. BOSULIF $32 2 payments
  10. IMBRUVICA Oncology $29 2 payments
  11. Other $347 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

37

Median for Internal Medicine: 777

Drug cost

$1,093

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Exemestane Generic 13 $674
Anastrozole Generic 24 $419

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $17
$17 — —
ONIVYDE
  • Ipsen Biopharmaceuticals, Inc $9
$9 — —
SOMATULINE DEPOT
  • Ipsen Biopharmaceuticals, Inc $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

37 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record